Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
The presentations will provide insight into SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming primary resistance to checkpoint therapy in advanced cancer patients. Combination therapy with selective TGFβ1 blockade may modulate the tumor microenvironment, allowing for immune cell infiltration and potential improvements in the response rate and survival time of cancer patients.
Specifically, the ACCP presentation will include new pharmacokinetic data from the Phase 1 dose escalation study (DRAGON Part A). The presentation at the World Clinical Biomarkers & CDx Summit includes a discussion of pre-clinical validation studies to assess biomarker utility, overcoming challenges and hurdles that create barriers to assay translatability to the clinic, and early clinical biomarker data including image-based analysis.
Details of the presentations are as follows:
ACCP Annual Meeting:
Title: Preliminary Population Pharmacokinetic Modeling of SRK-181 from Phase 1 Dose Escalation Study
Presentation Type: Poster 015
12th Annual World Clinical Biomarkers & CDx Summit:
Title: Development of a Comprehensive Biomarker Strategy for the Latent TGFβ1 Inhibitor SRK-181 Phase 1 Clinical Trial, DRAGON
Presentation Type: Oral
The presentations will be made available in the Publications & Posters section of Scholar Rock’s website following the conferences.
SRK-181 is a selective inhibitor of TGFβ1 activation being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies. TGFβ1 is the predominant TGFβ isoform expressed in many human tumor types. Based on analyses of various human tumors that are resistant to anti-PD-(L)1 therapy, data suggest TGFβ1 is a key contributor to the immunosuppressive tumor microenvironment, excluding and preventing entry of cytotoxic T cells into the tumor, thereby inhibiting anti-tumor immunity.(1)
(1) Martin et al., Sci. Transl. Med. 12:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, and progress and indication selection and development timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended